Search Results - "Hooshdaran, Nima"

p53 Activates the Long Noncoding RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis by Olivero, Christiane E., Martínez-Terroba, Elena, Zimmer, Joshua, Liao, Clara, Tesfaye, Ephrath, Hooshdaran, Nima, Schofield, Jeremy A., Bendor, Jordan, Fang, Dorthy, Simon, Matthew D., Zamudio, Jesse R., Dimitrova, Nadya

“…The tumor suppressor p53 transcriptionally activates target genes to suppress cellular proliferation during stress. p53 has also been implicated in the…”
Get full text

CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease by Zhao, Ning, Chopra, Shalini, Trepka, Kai, Wang, Yung-Hua, Sakhamuri, Sasank, Hooshdaran, Nima, Kim, Hyunjung, Zhou, Jie, Lim, Shion A, Leung, Kevin K, Egusa, Emily A, Zhu, Jun, Zhang, Li, Foye, Adam, Sriram, Renuka, Chan, Emily, Seo, Youngho, Feng, Felix Y, Small, Eric J, Chou, Jonathan, Wells, James A, Aggarwal, Rahul, Evans, Michael J

“…With the improvement in overall survival with 177Lu-PSMA 617, radioligand therapy (RLT) is now a viable option for patients with metastatic…”
Get full text

Temporal Control of the TGF-β Signaling Network by Mouse ESC MicroRNA Targets of Different Affinities by Kelly, Timothy J., Brümmer, Anneke, Hooshdaran, Nima, Tariveranmoshabad, Mito, Zamudio, Jesse R.

“…Although microRNAs (miRNAs) function in the control of embryonic stem cell (ESC) pluripotency, a systems-level understanding is still being developed. Through…”
Get full text

Elevated labile iron in castration–resistant prostate cancer is targetable with ferrous iron–activatable antiandrogen therapy by Gonciarz, Ryan L., Sakhamuri, Sasank, Hooshdaran, Nima, Kumar, Garima, Kim, Hyunjung, Evans, Michael J., Renslo, Adam R.

“…Clinical responses to second generation androgen signaling inhibitors (e.g., enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) are…”
Get full text

Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies by Zhao, Ning, Huang, Yangjie, Wang, Yung-Hua, Muir, Ryan K, Chen, Ying-Chu, Wei, Junnian, Hooshdaran, Nima, Viswanath, Pavithra, Seo, Youngho, Ruggero, Davide, Renslo, Adam R, Evans, Michael J

“…Although cancer has been known for decades to harbor an insatiable appetite for iron, only recently has the chemistry emerged to exploit this altered state…”
Get full text

In Vivo Profiling with 18F‑YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions by Kim, Hyunjung, Huang, Yangjie, Zhao, Ning, Wang, Yung-hua, Sakhamuri, Sasank, Chopra, Shalini, Hooshdaran, Nima, Sriram, Renuka, Aggarwal, Rahul, Evans, Michael J

“…Demonstrating target engagement in vivo is an important milestone in drug development, both to establish on target, on tissue interactions but also to identify…”
Get full text

In Vivo Profiling with 18 F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions by Kim, Hyunjung, Huang, Yangjie, Zhao, Ning, Wang, Yung-Hua, Sakhamuri, Sasank, Chopra, Shalini, Hooshdaran, Nima, Sriram, Renuka, Aggarwal, Rahul, Evans, Michael J

“…Demonstrating target engagement in vivo is an important milestone in drug development, both to establish on target, on tissue interactions but also to identify…”
Get full text

Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer by Chopra, Shalini, Trepka, Kai, Sakhamuri, Sasank, Carretero-González, Alberto, Zhu, Jun, Egusa, Emily, Zhou, Jie, Leung, Kevin, Zhao, Ning, Hooshdaran, Nima, Feng, Felix Y, Wells, James A, Chou, Jonathan, Evans, Michael J

“…Despite recent approvals for checkpoint inhibitors and antibody-drug conjugates targeting NECTIN4 or TROP2, metastatic bladder cancer remains incurable and new…”
Get full text